Persistent high-risk human papillomavirus (HPV) infection has been associated with increased risk for cervical precancerous lesions and cancer. The host’s genetic variability is known to play a role in the development of cervical cancer. The human leukocyte antigen (HLA) genes are highly polymorphic and have shown to be important risk determinants of HPV infection persistence and disease progression. HLA class I and II cell surface molecules regulate the host’s immune system by presenting HPV-derived peptides to T-cells. The activation of T-cell response may vary depending on the HLA allele polymorphism. The engagement of the T-cell receptor with the HPV peptide-HLA complex to create an active costimulatory signal is essential for the activation of the T-cell response. Functional peptide presentation by both HLA class I and II molecules is needed to activate efficient helper and effector T-cell responses in HPV infection recognition and clearance. Some of these HLA risk alleles could also be used as preventive tools in the detection of HPV-induced cervical lesions and cancer. These HLA alleles, together with HPV vaccines, could potentially offer possible solutions for reducing HPV-induced cervical cancer as well as other HPV-related cancers.

1.
Giroglou
T
,
Florin
L
,
Schäfer
F
,
Streeck
RE
,
Sapp
M
.
Human papillomavirus infection requires cell surface heparan sulfate
.
J Virol
.
2001
Feb
;
75
(
3
):
1565
70
.
[PubMed]
0022-538X
2.
Finnen
RL
,
Erickson
KD
,
Chen
XS
,
Garcea
RL
.
Interactions between papillomavirus L1 and L2 capsid proteins
.
J Virol
.
2003
Apr
;
77
(
8
):
4818
26
.
[PubMed]
0022-538X
3.
Sapp
M
,
Bienkowska-Haba
M
.
Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus
.
FEBS J
.
2009
Dec
;
276
(
24
):
7206
16
.
[PubMed]
1742-464X
4.
Florin
L
,
Sapp
M
,
Spoden
GA
.
Host-cell factors involved in papillomavirus entry
.
Med Microbiol Immunol (Berl)
.
2012
Nov
;
201
(
4
):
437
48
.
[PubMed]
0300-8584
5.
Reinson
T
,
Henno
L
,
Toots
M
,
Ustav
M
 Jr
,
Ustav
M
.
The Cell Cycle Timing of Human Papillomavirus DNA Replication
.
PLoS One
.
2015
Jul
;
10
(
7
):
e0131675
.
[PubMed]
1932-6203
6.
Stubenrauch
F
,
Laimins
LA
.
Human papillomavirus life cycle: active and latent phases
.
Semin Cancer Biol
.
1999
Dec
;
9
(
6
):
379
86
.
[PubMed]
1044-579X
7.
Schelhaas
M
,
Shah
B
,
Holzer
M
,
Blattmann
P
,
Kühling
L
,
Day
PM
, et al.
Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis
.
PLoS Pathog
.
2012
;
8
(
4
):
e1002657
.
[PubMed]
1553-7366
8.
Doorbar
J
,
Quint
W
,
Banks
L
,
Bravo
IG
,
Stoler
M
,
Broker
TR
, et al.
The biology and life-cycle of human papillomaviruses
.
Vaccine
.
2012
Nov
;
30
Suppl 5
:
F55
70
.
[PubMed]
0264-410X
9.
Vallejo-Ruiz
V
,
Velázquez-Márquez
N
,
Sánchez-Alonso
P
,
Santos-López
G
,
Reyes-Leyva
J
.
[Human papillomavirus E7 oncoprotein and its role in the cell transformation]
.
Rev Med Inst Mex Seguro Soc
.
2015
;
53
Suppl 2
:
S172
7
.
[PubMed]
2448-5667
10.
Li
L
,
Xu
C
,
Long
J
,
Shen
D
,
Zhou
W
,
Zhou
Q
, et al.
E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines
.
Oncotarget
.
2015
Sep
;
6
(
27
):
23930
43
.
[PubMed]
1949-2553
11.
Moody
CA
,
Laimins
LA
.
Human papillomavirus oncoproteins: pathways to transformation
.
Nat Rev Cancer
.
2010
Aug
;
10
(
8
):
550
60
.
[PubMed]
1474-175X
12.
Luhn
P
,
Walker
J
,
Schiffman
M
,
Zuna
RE
,
Dunn
ST
,
Gold
MA
, et al.
The role of co-factors in the progression from human papillomavirus infection to cervical cancer
.
Gynecol Oncol
.
2013
Feb
;
128
(
2
):
265
70
.
[PubMed]
0090-8258
13.
Hong
S
,
Laimins
LA
.
Manipulation of the innate immune response by human papillomaviruses
.
Virus Res
.
2017
Mar
;
231
:
34
40
.
[PubMed]
0168-1702
14.
Lester
SN
,
Li
K
.
Toll-like receptors in antiviral innate immunity
.
J Mol Biol
.
2014
Mar
;
426
(
6
):
1246
64
.
[PubMed]
0022-2836
15.
Bodily
J
,
Laimins
LA
.
Persistence of human papillomavirus infection: keys to malignant progression
.
Trends Microbiol
.
2011
Jan
;
19
(
1
):
33
9
.
[PubMed]
0966-842X
16.
Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium
.
Nature
.
1999
Oct
;
401
(
6756
):
921
3
.
[PubMed]
0028-0836
17.
Klein
J
,
Sato
A
.
The HLA system. First of two parts
.
N Engl J Med
.
2000
Sep
;
343
(
10
):
702
9
.
[PubMed]
0028-4793
18.
Kim
CJ
,
Jeong
JK
,
Park
M
,
Park
TS
,
Park
TC
,
Namkoong
SE
, et al.
HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions
.
Gynecol Oncol
.
2003
May
;
89
(
2
):
210
7
.
[PubMed]
0090-8258
19.
Horton
R
,
Wilming
L
,
Rand
V
,
Lovering
RC
,
Bruford
EA
,
Khodiyar
VK
, et al.
Gene map of the extended human MHC
.
Nat Rev Genet
.
2004
Dec
;
5
(
12
):
889
99
.
[PubMed]
1471-0056
20.
Munoz
N
,
Bosch
FX
,
de Sanjose
S
,
Herrero
R
,
Castellsague
X
,
Shah
KV
,
Snijders
P
,
Meijer
C
:
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer.
New England Journal of Medicine [New Engl J Med ] Vol 348
2003
;348:518-527.
21.
Johnston
C
.
Quantitative tests for human papillomavirus
.
Lancet
.
2000
Jun
;
355
(
9222
):
2179
80
.
[PubMed]
0140-6736
22.
Krul
EJ
,
Schipper
RF
,
Schreuder
GM
,
Fleuren
GJ
,
Kenter
GG
,
Melief
CJ
.
HLA and susceptibility to cervical neoplasia
.
Hum Immunol
.
1999
Apr
;
60
(
4
):
337
42
.
[PubMed]
0198-8859
23.
Castle
PE
,
Wheeler
CM
,
Solomon
D
,
Schiffman
M
,
Peyton
CL
;
ALTS Group
.
Interlaboratory reliability of Hybrid Capture 2
.
Am J Clin Pathol
.
2004
Aug
;
122
(
2
):
238
45
.
[PubMed]
0002-9173
24.
Jin
P
,
Wang
E
: Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling. J Transl Med
2003
;1:8-5876-1-8.
25.
de Araujo Souza
PS
,
Sichero
L
,
Maciag
PC
.
HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer
.
Future Oncol
.
2009
Apr
;
5
(
3
):
359
70
.
[PubMed]
1479-6694
26.
Delves
PJ
,
Roitt
IM
.
The immune system. First of two parts
.
N Engl J Med
.
2000
Jul
;
343
(
1
):
37
49
.
[PubMed]
0028-4793
27.
Hildesheim
A
,
Wang
SS
.
Host and viral genetics and risk of cervical cancer: a review
.
Virus Res
.
2002
Nov
;
89
(
2
):
229
40
.
[PubMed]
0168-1702
28.
Syrjänen
S
,
Shabalova
IP
,
Petrovichev
N
,
Kozachenko
VP
,
Zakharova
T
,
Pajanidi
J
, et al.
Human papillomavirus testing and conventional pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former soviet union
.
J Low Genit Tract Dis
.
2002
Apr
;
6
(
2
):
97
110
.
[PubMed]
1089-2591
29.
Koopman
LA
,
Corver
WE
,
van der Slik
AR
,
Giphart
MJ
,
Fleuren
GJ
.
Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer
.
J Exp Med
.
2000
Mar
;
191
(
6
):
961
76
.
[PubMed]
0022-1007
30.
Dong
DD
,
Yang
H
,
Li
K
,
Xu
G
,
Song
LH
,
Fan
XL
, et al.
Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response
.
Reprod Sci
.
2010
Aug
;
17
(
8
):
718
23
.
[PubMed]
1933-7191
31.
Carosella
ED
,
Moreau
P
,
Lemaoult
J
,
Rouas-Freiss
N
.
HLA-G: from biology to clinical benefits
.
Trends Immunol
.
2008
Mar
;
29
(
3
):
125
32
.
[PubMed]
1471-4906
32.
Song
D
,
Li
H
,
Li
H
,
Dai
J
.
Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer
.
Oncol Lett
.
2015
Aug
;
10
(
2
):
600
6
.
[PubMed]
1792-1074
33.
Georgopoulos
NT
,
Proffitt
JL
,
Blair
GE
.
Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins
.
Oncogene
.
2000
Oct
;
19
(
42
):
4930
5
.
[PubMed]
0950-9232
34.
Piguet
V
.
Receptor modulation in viral replication: HIV, HSV, HHV-8 and HPV: same goal, different techniques to interfere with MHC-I antigen presentation
.
Curr Top Microbiol Immunol
.
2005
;
285
:
199
217
.
[PubMed]
0070-217X
35.
Venuti
A
,
Paolini
F
,
Nasir
L
,
Corteggio
A
,
Roperto
S
,
Campo
MS
,
Borzacchiello
G
:
Papillomavirus E5: the smallest oncoprotein with many functions.
Mol Cancer
2011
;10:140-4598-10-140.
36.
Ganguly
N
,
Parihar
SP
.
Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis
.
J Biosci
.
2009
Mar
;
34
(
1
):
113
23
.
[PubMed]
0250-5991
37.
Ellis
JR
,
Keating
PJ
,
Baird
J
,
Hounsell
EF
,
Renouf
DV
,
Rowe
M
, et al.
The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer
.
Nat Med
.
1995
May
;
1
(
5
):
464
70
.
[PubMed]
1078-8956
38.
Qiu
X
,
Zhang
F
,
Chen
D
,
Azad
AK
,
Zhang
L
,
Yuan
Y
, et al.
HLA-B*07 is a high risk allele for familial cervical cancer
.
Asian Pac J Cancer Prev
.
2011
;
12
(
10
):
2597
600
.
[PubMed]
2476-762X
39.
Bahls
L
,
Yamakawa
R
,
Zanão
K
,
Alfieri
D
,
Flauzino
T
,
Delongui
F
, et al.
Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer
.
Int J Mol Sci
.
2017
Aug
;
18
(
9
):
E1478
.
[PubMed]
1661-6596
40.
Leo
PJ
,
Madeleine
MM
,
Wang
S
,
Schwartz
SM
,
Newell
F
,
Pettersson-Kymmer
U
, et al.
Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study
.
PLoS Genet
.
2017
Aug
;
13
(
8
):
e1006866
.
[PubMed]
1553-7390
41.
Gokhale
P
,
Mania-Pramanik
J
,
Sonawani
A
,
Idicula-Thomas
S
,
Kerkar
S
,
Tongaonkar
H
, et al.
Cervical cancer in Indian women reveals contrasting association among common sub-family of HLA class I alleles
.
Immunogenetics
.
2014
Dec
;
66
(
12
):
683
91
.
[PubMed]
0093-7711
42.
Madeleine
MM
,
Brumback
B
,
Cushing-Haugen
KL
,
Schwartz
SM
,
Daling
JR
,
Smith
AG
, et al.
Human leukocyte antigen class II and cervical cancer risk: a population-based study
.
J Infect Dis
.
2002
Dec
;
186
(
11
):
1565
74
.
[PubMed]
0022-1899
43.
Wang
SS
,
Hildesheim
A
,
Gao
X
,
Schiffman
M
,
Herrero
R
,
Bratti
MC
, et al.
Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies
.
J Infect Dis
.
2002
Sep
;
186
(
5
):
598
605
.
[PubMed]
0022-1899
44.
Ferguson
R
,
Ramanakumar
AV
,
Richardson
H
,
Tellier
PP
,
Coutlée
F
,
Franco
EL
, et al.
Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence
.
Hum Immunol
.
2011
Apr
;
72
(
4
):
337
41
.
[PubMed]
0198-8859
45.
Song
MJ
,
Lee
CW
,
Kim
JH
,
Lee
SJ
,
Kim
CJ
,
Hur
SY
, et al.
Association of KIR genes and HLA-C alleles with HPV-related uterine cervical disease in Korean women
.
Tissue Antigens
.
2013
Mar
;
81
(
3
):
164
70
.
[PubMed]
0001-2815
46.
Chan
PK
,
Cheung
JL
,
Cheung
TH
,
Lin
CK
,
Tam
AO
,
Chan
DP
, et al.
HLA-B alleles, high-risk HPV infection and risk for cervical neoplasia in southern Chinese women
.
Int J Cancer
.
2006
Mar
;
118
(
6
):
1430
5
.
[PubMed]
0020-7136
47.
Simões
RT
,
Gonçalves
MA
,
Castelli
EC
,
Júnior
CM
,
Bettini
JS
,
Discorde
ML
, et al.
HLA-G polymorphisms in women with squamous intraepithelial lesions harboring human papillomavirus
.
Mod Pathol
.
2009
Aug
;
22
(
8
):
1075
82
.
[PubMed]
0893-3952
48.
Malissen
B
,
Tamoutounour
S
,
Henri
S
.
The origins and functions of dendritic cells and macrophages in the skin
.
Nat Rev Immunol
.
2014
Jun
;
14
(
6
):
417
28
.
[PubMed]
1474-1733
49.
Stanley
MA
,
Sterling
JC
.
Host responses to infection with human papillomavirus
.
Curr Probl Dermatol
.
2014
;
45
:
58
74
.
[PubMed]
1421-5721
50.
Merad
M
,
Sathe
P
,
Helft
J
,
Miller
J
,
Mortha
A
.
The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting
.
Annu Rev Immunol
.
2013
;
31
(
1
):
563
604
.
[PubMed]
0732-0582
51.
Sallusto
F
,
Geginat
J
,
Lanzavecchia
A
.
Central memory and effector memory T cell subsets: function, generation, and maintenance
.
Annu Rev Immunol
.
2004
;
22
(
1
):
745
63
.
[PubMed]
0732-0582
52.
Steele
JC
,
Mann
CH
,
Rookes
S
,
Rollason
T
,
Murphy
D
,
Freeth
MG
, et al.
T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia
.
Br J Cancer
.
2005
Jul
;
93
(
2
):
248
59
.
[PubMed]
0007-0920
53.
de Jong
A
,
van Poelgeest
MI
,
van der Hulst
JM
,
Drijfhout
JW
,
Fleuren
GJ
,
Melief
CJ
, et al.
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6
.
Cancer Res
.
2004
Aug
;
64
(
15
):
5449
55
.
[PubMed]
0008-5472
54.
Welters
MJ
,
Kenter
GG
,
Piersma
SJ
,
Vloon
AP
,
Löwik
MJ
,
Berends-van der Meer
DM
, et al.
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
.
Clin Cancer Res
.
2008
Jan
;
14
(
1
):
178
87
.
[PubMed]
1078-0432
55.
Romagnani
S
: T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol
2000
;85:9-18; quiz 18, 21.
56.
Ito
H
,
Seishima
M
.
Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell
.
J Biomed Biotechnol
.
2010
;
2010
:
641757
.
[PubMed]
1110-7243
57.
Zou
W
,
Restifo
NP
.
T(H)17 cells in tumour immunity and immunotherapy
.
Nat Rev Immunol
.
2010
Apr
;
10
(
4
):
248
56
.
[PubMed]
1474-1733
58.
Kryczek
I
,
Wei
S
,
Szeliga
W
,
Vatan
L
,
Zou
W
.
Endogenous IL-17 contributes to reduced tumor growth and metastasis
.
Blood
.
2009
Jul
;
114
(
2
):
357
9
.
[PubMed]
0006-4971
59.
He
D
,
Li
H
,
Yusuf
N
,
Elmets
CA
,
Li
J
,
Mountz
JD
, et al.
IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells
.
J Immunol
.
2010
Mar
;
184
(
5
):
2281
8
.
[PubMed]
0022-1767
60.
Maniati
E
,
Soper
R
,
Hagemann
T
.
Up for Mischief? IL-17/Th17 in the tumour microenvironment
.
Oncogene
.
2010
Oct
;
29
(
42
):
5653
62
.
[PubMed]
0950-9232
61.
Numasaki
M
,
Watanabe
M
,
Suzuki
T
,
Takahashi
H
,
Nakamura
A
,
McAllister
F
, et al.
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis
.
J Immunol
.
2005
Nov
;
175
(
9
):
6177
89
.
[PubMed]
0022-1767
62.
Mills
KH
,
McGuirk
P
.
Antigen-specific regulatory T cells—their induction and role in infection
.
Semin Immunol
.
2004
Apr
;
16
(
2
):
107
17
.
[PubMed]
1044-5323
63.
Jaafar
F
,
Righi
E
,
Lindstrom
V
,
Linton
C
,
Nohadani
M
,
Van Noorden
S
, et al.
Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer
.
Am J Pathol
.
2009
Oct
;
175
(
4
):
1525
35
.
[PubMed]
0002-9440
64.
Scott
ME
,
Ma
Y
,
Kuzmich
L
,
Moscicki
AB
.
Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3
.
Int J Cancer
.
2009
Mar
;
124
(
6
):
1379
83
.
[PubMed]
0020-7136
65.
Molling
JW
,
de Gruijl
TD
,
Glim
J
,
Moreno
M
,
Rozendaal
L
,
Meijer
CJ
, et al.
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia
.
Int J Cancer
.
2007
Oct
;
121
(
8
):
1749
55
.
[PubMed]
0020-7136
66.
Torres-Poveda
K
,
Bahena-Román
M
,
Madrid-González
C
,
Burguete-García
AI
,
Bermúdez-Morales
VH
,
Peralta-Zaragoza
O
, et al.
Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia
.
World J Clin Oncol
.
2014
Oct
;
5
(
4
):
753
63
.
[PubMed]
2218-4333
67.
Zhu
H
,
Luo
H
,
Shen
Z
,
Hu
X
,
Sun
L
,
Zhu
X
.
Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer
.
Tumour Biol
.
2016
Jun
;
37
(
6
):
7075
83
.
[PubMed]
1010-4283
68.
Madeleine
MM
,
Johnson
LG
,
Smith
AG
,
Hansen
JA
,
Nisperos
BB
,
Li
S
, et al.
Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk
.
Cancer Res
.
2008
May
;
68
(
9
):
3532
9
.
[PubMed]
0008-5472
69.
Zhang
X
,
Lv
Z
,
Yu
H
,
Wang
F
,
Zhu
J
.
The HLA-DQB1 gene polymorphisms associated with cervical cancer risk: A meta-analysis
.
Biomed Pharmacother
.
2015
Jul
;
73
:
58
64
.
[PubMed]
0753-3322
70.
Mahmud
S
,
Robinson
K
,
Richardson
H
,
Tellier
P
,
Ferenczy
A
,
Roger
M
,
Coutlee
F
,
Franco
E
: HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis.
2007
; 1;196(1):82-83-90.
71.
Hu
Y
,
Wu
JZ
,
Zhu
H
,
Zhang
SH
,
Zhu
YY
,
Wu
YY
, et al.
Association of HLA-DRB1, HLA-DQB1 Polymorphisms with HPV 16 E6 Variants among Young Cervical Cancer Patients in China
.
J Cancer
.
2017
Jul
;
8
(
12
):
2401
9
.
[PubMed]
0378-2360
72.
Ivansson
EL
,
Magnusson
JJ
,
Magnusson
PK
,
Erlich
HA
,
Gyllensten
UB
.
MHC loci affecting cervical cancer risk: distinguishing the effects of HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2
.
Genes Immun
.
2008
Oct
;
9
(
7
):
613
23
.
[PubMed]
1466-4879
73.
Wang
SS
,
Wheeler
CM
,
Hildesheim
A
,
Schiffman
M
,
Herrero
R
,
Bratti
MC
, et al.
Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica
.
J Infect Dis
.
2001
Nov
;
184
(
10
):
1310
4
.
[PubMed]
0022-1899
74.
Safaeian
M
,
Johnson
LG
,
Yu
K
,
Wang
SS
,
Gravitt
PE
,
Hansen
JA
, et al.
Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma
.
Front Oncol
.
2014
Jun
;
4
:
119
.
[PubMed]
2234-943X
75.
Matsumoto
K
,
Maeda
H
,
Oki
A
,
Takatsuka
N
,
Yasugi
T
,
Furuta
R
, et al.;
Japan HPV and Cervical Cancer (JHACC) Study Group
.
Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: at which step of multistage carcinogenesis?
Cancer Sci
.
2015
Oct
;
106
(
10
):
1448
54
.
[PubMed]
1347-9032
76.
Sastre-Garau
X
,
Loste
MN
,
Vincent-Salomon
A
,
Favre
M
,
Mouret
E
,
de la Rochefordiere
A
, et al.
Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix
.
Int J Cancer
.
1996
Jun
;
69
(
3
):
159
64
.
[PubMed]
0020-7136
77.
Menier
C
,
Prevot
S
,
Carosella
ED
,
Rouas-Freiss
N
.
Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology
.
Hum Immunol
.
2009
Dec
;
70
(
12
):
1006
9
.
[PubMed]
0198-8859
78.
Amiot
L
,
Ferrone
S
,
Grosse-Wilde
H
,
Seliger
B
.
Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?
Cell Mol Life Sci
.
2011
Feb
;
68
(
3
):
417
31
.
[PubMed]
1420-682X
79.
Chabeda
A
,
Yanez
RJ
,
Lamprecht
R
,
Meyers
AE
,
Rybicki
EP
,
Hitzeroth
II
.
Therapeutic vaccines for high-risk HPV-associated diseases
.
Papillomavirus Res
.
2018
Jun
;
5
:
46
58
.
[PubMed]
2405-8521
80.
Skeate
JG
,
Woodham
AW
,
Einstein
MH
,
Da Silva
DM
,
Kast
WM
.
Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases
.
Hum Vaccin Immunother
.
2016
Jun
;
12
(
6
):
1418
29
.
[PubMed]
2164-5515
81.
Khong
H
,
Overwijk
WW
: Adjuvants for peptide-based cancer vaccines. J Immunother Cancer
2016
;4:56-016-0160-y. eCollection 2016.
82.
Yang
A
,
Farmer
E
,
Lin
J
,
Wu
TC
,
Hung
CF
.
The current state of therapeutic and T cell-based vaccines against human papillomaviruses
.
Virus Res
.
2017
Mar
;
231
:
148
65
.
[PubMed]
0168-1702
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.